Zura Bio Limited filed its Form 10-Q with the U.S. Securities and Exchange Commission on August 11, 2026, covering the quarterly period ended June 30, 2026.

Key Highlights

  • Shares Outstanding: As of August 11, 2026, the company had 95,829,137 Class A Ordinary Shares outstanding.
  • Filer Status: Zura Bio is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
  • No Approved Products: According to the filing, the company has not completed any clinical trials and has no products approved for commercial sale.
  • Operating Losses: The company disclosed it "has incurred significant losses since inception, and expects to incur significant losses for the foreseeable future."
  • Capital Dependence: The filing states the company "will continue to require substantial additional capital to finance our operations."
  • Shell Company Status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.

Zura Bio's Financial Position and Development Stage Operations

Zura Bio Limited (NASDAQ:ZURA), incorporated in the Cayman Islands and headquartered in Henderson, Nevada, submitted its quarterly report for the period ended June 30, 2026. The company is a clinical-stage biopharmaceutical entity that, according to the filing, relies on third-party contract development manufacturing organizations for the manufacture of clinical materials and on contract research organizations to conduct its preclinical studies and clinical trials.

The filing describes the company as having no revenue-generating approved products. Zura Bio disclosed that it expects to incur significant losses for the foreseeable future and may not achieve or sustain profitability. The company noted it may need to "delay, reduce, and/or eliminate one or more of our development programs or future commercialization efforts" if it is unable to raise additional capital when needed or on acceptable terms. The filing also cited risks including the ability to attract and retain key personnel and potential challenges with vendors and other third parties.

The company identified a range of risks to its business, including competitive pressures from other companies worldwide, reliance on third parties for manufacturing and clinical operations, and uncertainties around regulatory approval for its product candidates. The filing notes that these forward-looking statements "are not guarantees of performance" and are subject to the cautionary language included throughout the Quarterly Report and in the company's Annual Report on Form 10-K for the year ended December 31, 2025.

What Was Disclosed

Zura Bio Limited filed a Form 10-Q for the quarter ended June 30, 2026, reporting 95,829,137 Class A Ordinary Shares outstanding as of August 11, 2026. The company disclosed it has no approved products, has incurred significant losses since inception, and continues to require additional capital to fund operations.